U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451002) titled 'A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France' on Jan. 26.
Brief Summary: This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior of metastatic hormone-sensitive prostate cancer (mHSPC) participants treated with apalutamide during the first year of continued treatment.
Study Start Date: Dec. 18, 2025
Study Type: OBSERVATIONAL
Condition:
Prostatic Neoplasms
Metastatic Hormone-sensitive Prostate Cancer
Recruitment Status: RECRUITING
Sponsor...